Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather M Shaw

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Oncotargets and Therapy|September 18, 2013
Emerging treatment options for recurrent ovarian cancer: the potential role of olaparibHeather M Shaw, Marcia Hall
Expert Review of Anticancer Therapy|April 27, 2013
Vemurafenib in melanomaHeather M Shaw, Paul D Nathan
Melanoma Research|November 6, 2018
Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitisRomaana Mir, Heather M Shaw, Paul D Nathan
Therapeutic Advances in Medical Oncology|March 27, 2023
Tebentafusp: a first-in-class treatment for metastatic uveal melanomaSarah Howlett, Thomas J Carter, Heather M Shaw, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2020
Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implicationsKarla A Lee, Heather M Shaw, Veronique Bataille, et al.
Molecular Biology of the Cell|June 11, 2010
The retinoblastoma protein modulates Tbx2 functional specificityKeith W Vance, Heather M Shaw, Mercedes Rodriguez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2009
A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumorsAlison H M Reid, Andrew Protheroe, Gerhardt Attard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumorsPaul Haluska, Heather M Shaw, Gretchen N Batzel, et al.
The Journal of Investigative Dermatology|November 30, 2012
Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasionSuzanah C Boyd, Branka Mijatov, Gulietta M Pupo, et al.
Ebiomedicine|August 25, 2022
Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanomaNiccolò Rossi, Karla A Lee, Maria V Bermudez, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Oncotargets and Therapy|September 18, 2013
Emerging treatment options for recurrent ovarian cancer: the potential role of olaparibHeather M Shaw, Marcia Hall
Expert Review of Anticancer Therapy|April 27, 2013
Vemurafenib in melanomaHeather M Shaw, Paul D Nathan
Melanoma Research|November 6, 2018
Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitisRomaana Mir, Heather M Shaw, Paul D Nathan
Therapeutic Advances in Medical Oncology|March 27, 2023
Tebentafusp: a first-in-class treatment for metastatic uveal melanomaSarah Howlett, Thomas J Carter, Heather M Shaw, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2020
Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implicationsKarla A Lee, Heather M Shaw, Veronique Bataille, et al.
Molecular Biology of the Cell|June 11, 2010
The retinoblastoma protein modulates Tbx2 functional specificityKeith W Vance, Heather M Shaw, Mercedes Rodriguez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2009
A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumorsAlison H M Reid, Andrew Protheroe, Gerhardt Attard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumorsPaul Haluska, Heather M Shaw, Gretchen N Batzel, et al.
The Journal of Investigative Dermatology|November 30, 2012
Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasionSuzanah C Boyd, Branka Mijatov, Gulietta M Pupo, et al.
Ebiomedicine|August 25, 2022
Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanomaNiccolò Rossi, Karla A Lee, Maria V Bermudez, et al.
Pageof 2